The cancer therapy developer boosted a series B round led by Novo and backed by Celgene to $75.2m, with both corporates contributing to the latest tranche.
US-based synthetic cancer drug developer Cyteir Therapeutics increased a series B round led by pharmaceutical firm Novo to $75.2m yesterday.
The company added $40.2m to close the round, which included pharmaceutical company Celgene, Osage University Partners (OUP), Droia Oncology Ventures, Lightstone Ventures and Venrock. The latter three had provided the round’s $29m first tranche in March 2018.
Founded in 2012, Cyteir is looking to commercialise small molecule oncological drugs targeting enzymes known as cytidine deaminases, which damage the body’s DNA…
